Shanghai-based RNA therapeutics specialist Rona Therapeutics has entered into a licensing agreement with French pharmaceutical giant Sanofi, securing exclusive worldwide rights to Sanofi’s siRNA platform of chemical modification and delivery moiety, as well as rights to four pre-clinical candidates targeting undisclosed indications.
Deal Highlights
The agreement significantly expands Rona’s pipeline in both liver and non-liver indications, positioning the firm as an industry leader in oligonucleotide modification, delivery, and RNA biology. The siRNA platform, based on novel nucleotide analogs and conjugation moiety, has demonstrated enhanced stability and prolonged in vivo duration of action, with potential for therapeutic silencing of target genes across various tissue types.
Sanofi’s Retained Rights
Under the terms, Sanofi retains the option to select neuro and muscular candidates discovered using the siRNA platform for territories outside Greater China (mainland China, Hong Kong, Taiwan, and Macao). Rona will make an upfront payment to Sanofi and commit to development and commercial milestones and royalties on future net sales, with specific financial details undisclosed.
Rona’s Development Plans
Rona plans to advance the four pre-clinical candidates in metabolic, neurological, and ocular diseases, leveraging the siRNA platform’s capabilities to expand its therapeutic reach.-Fineline Info & Tech
